- Home
- ALV vs EXAS Comparison
ALV vs EXAS Comparison
Compare ALV & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALV
- EXAS
- Stock Information
- Founded
- ALV 1953
- EXAS 1995
- Country
- ALV Sweden
- EXAS United States
- Employees
- ALV N/A
- EXAS N/A
- Industry
- ALV Auto Parts:O.E.M.
- EXAS Medical Specialities
- Sector
- ALV Consumer Discretionary
- EXAS Health Care
- Exchange
- ALV Nasdaq
- EXAS Nasdaq
- Market Cap
- ALV 9.7B
- EXAS 11.0B
- IPO Year
- ALV 1997
- EXAS N/A
- Fundamental
- Price
- ALV $116.80
- EXAS $64.69
- Analyst Decision
- ALV Buy
- EXAS Strong Buy
- Analyst Count
- ALV 9
- EXAS 21
- Target Price
- ALV $131.33
- EXAS $69.24
- AVG Volume (30 Days)
- ALV 761.4K
- EXAS 2.1M
- Earning Date
- ALV 10-17-2025
- EXAS 11-03-2025
- Dividend Yield
- ALV 2.91%
- EXAS N/A
- EPS Growth
- ALV 25.57
- EXAS N/A
- EPS
- ALV 9.69
- EXAS N/A
- Revenue
- ALV $10,614,000,000.00
- EXAS $2,939,949,000.00
- Revenue This Year
- ALV $4.45
- EXAS $16.68
- Revenue Next Year
- ALV $4.26
- EXAS $12.12
- P/E Ratio
- ALV $12.05
- EXAS N/A
- Revenue Growth
- ALV 0.85
- EXAS 12.55
- 52 Week Low
- ALV $75.49
- EXAS $38.81
- 52 Week High
- ALV $129.54
- EXAS $72.83
- Technical
- Relative Strength Index (RSI)
- ALV 42.56
- EXAS 72.40
- Support Level
- ALV $114.50
- EXAS $62.39
- Resistance Level
- ALV $118.76
- EXAS $65.44
- Average True Range (ATR)
- ALV 2.58
- EXAS 1.61
- MACD
- ALV -0.06
- EXAS -0.17
- Stochastic Oscillator
- ALV 32.76
- EXAS 89.21
About ALV Autoliv Inc.
Autoliv Inc is the world-wide leader in passive safety components and systems for the auto industry. Products include seat belts, frontal air bags, side-impact air bags, air bag inflators, and steering wheels. The Renault-Nissan-Mitsubishi alliance is the company's largest customer at 10% of 2023 revenue, with Stellantis accounting for 10% and Volkswagen 9%. At 34% of 2023 revenue, the Americas was Autoliv's largest geographic region, followed by Europe at 27%, China at 20%, and rest of world at 19%.
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.